ClinicalTrials.gg
TerminatedNCT06245941Updated Jan 5, 2026

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

A Phase 1/2 interventional study of TQ05105 tablets and TQB3909 tablets in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.

Enrollment
7th of 10
21 · median 28
Started
2024
with 1 other
Phase 1/2
2 of 10
1 open now
Registered
4th of 10
by date

Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 7th largest by enrollment, is one of 2 that started in 2024, is one of 2 in phase 1/2, and was the 4th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the study and signed with good compliance;
  • Age: 18 or above (when signing the informed consent form); (ECOG) performance status (PS) score of 0 to 2; ≥ 24 weeks;
  • Patients diagnosed with Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV-MF), or post essential thrombocythemia myelofibrosis (post-ET-MF);
  • Those with moderate or high risk myelofibrosis evaluated according to Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria, or those with high risk myelofibrosis according to National Comprehensive Cancer Network (NCCN) guidelines prognostic grading criteria;
  • Patients with poor efficacy of JAK inhibitors (for monotherapy of TQB3909, phase Ib and phase II cohort 2);
  • Patients who had not received JAK inhibitor treatment (for phase Ib and phase II cohort 2)
  • Spleen enlargement;
  • Peripheral blood primary cells and bone marrow primary cells are ≤10%;
  • No growth factor, colony stimulating factor, thrombopoietin or transfusion was received within 2 weeks before the examination, and the blood routine indexes met the requirements within 7 days before the first administration
  • The Main organ function is normal;
  • Men and women of childbearing age should agree to use measures during the study period and within 6 months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received stem cell transplantation, or received autologous stem cell transplantation within 3 months before the first administration, or recently planned stem cell transplantation;
  • Patients who have previously received BCL-2 inhibitor combined with JAK inhibitor therapy;
  • Patients who have previously undergone splenectomy, or received splenic radiotherapy within 6 months before the first administration;
  • Other within 3 years prior to first administration or currently present.
  • Patients with multiple factors affecting oral or absorption of drugs;
  • Major surgical treatment or significant traumatic injury within 4 weeks prior to first administration;
  • Presence of congenital bleeding disorder and congenital coagulopathy;
  • Patients who had arterial/venous thrombosis events within 6 months before the first administration.
  • Have a history of mental drug abuse, or have a mental disorder.
  • Active or uncontrolled severe infection;
  • Active virus (HBV) infection, or virus (HCV) infection , or active Corona Virus Disease 2019 (COVID-19) infection;
  • Patients with grade III or above congestive heart failure, unstable angina pectoris or myocardial infarction, or arrhythmia requiring treatment, or prolongation within 6 months before the first administration;
  • Unsatisfactory blood pressure control despite standard therapy;
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Patients newly diagnosed with pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before the first administration;
  • Patients with a history of immunodeficiency disease or organ transplantation;
  • Patients with epilepsy requiring treatment;
  • Patients with uncontrolled pleural effusion, pericardial effusion or ascites;
  • There is a history of attenuated inoculation within 4 weeks before the first administration, or attenuated live vaccine inoculation was planned during the study period.
  • People with known to the study drug and ;
  • Patients diagnosed as active diseases within 2 years before the first administration;
  • Those who participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first administration
  • Any MF treatment drugs, any immunomodulators, or any were used within 2 weeks prior to the first dose
  • According to the judgment of the investigators, some situations seriously endanger the safety of the subjects or affect the subjects to complete the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    TQB3909 Tablets

    TQB3909 Tablets, orally administered. 28 days as a treatment cycle.

    Drug: TQB3909 tablets

  • Experimental
    TQ05105 Tablets combined with TQB3909 Tablets

    TQ05105 Tablets combined with TQB3909 Tablets, orally administered. 28 days as a treatment cycle.

    Drug: TQ05105 tablets · Drug: TQB3909 tablets

Interventions

  • TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor

  • TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.

06

What researchers measure

Primary outcomes

  1. Maximal tolerance dose (MTD)

    If dose limiting toxicity (DLT) occurs in 2 or more subjects in a given dose group, the dose level in the previous dose group is considered as MTD.

    Time frame: Up to 2 years.

  2. Recommended phase II dose (RP2D)

    The RP2D is defined as the lower dose level to MTD based on the safety profile

    Time frame: Up to 2 years

  3. 35% reduction in spleen volume (SVR35) at week 24

    The proportion of subjects with a ≥35% reduction in spleen volume from baseline at the end of treatment at week 24

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Optimum effective rate

    The proportion of subjects with at least once spleen volume reduction ≥ 35% from baseline

    Time frame: Up to 120 weeks

  2. Onset time of splenic response

    The time interval from the first administration to the date when the spleen volume was reduced by ≥ 35 % from baseline

    Time frame: Up to 120 weeks

  3. Duration of maintenance of at least 35% Reduction in Spleen Volume (DoMSR)

    The time between the date when the spleen volume reduction ≥ 35% from baseline occurs for the first time and the date when the spleen volume reduction is \< 35% from baseline.

    Time frame: Up to 120 weeks

  4. Percentage change in spleen volume from baseline

    Percentage change in spleen volume of subjects from baseline after treatment.

    Time frame: Up to 60 weeks

  5. SVR35 at week 60

    The proportion of subjects with a ≥35% reduction in spleen volume compared to baseline after treatment at week 60.

    Time frame: Up to 60 weeks

  6. Myeloproliferative neoplasm - Symptom Assessment Form - Total Symptom Score (MPN-SAF-TSS)

    The proportion of subjects whose total symptom score of MPN-SAF TSS decreased by more than 50% from baseline. MPN-SAF-TSS is a tool for evaluating the disease burden of patients with myeloproliferative neoplasms. Each symptom is scored according to the severity, from asymptomatic (0 points) to the most serious (10 points), a total of 10 levels, the sum of 10 symptom scores is MPN-SAF-TSS score. The higher the score, the more severe the symptoms are.

    Time frame: Up to 60 weeks

  7. MPN-SAF-TSS decrease

    The time and duration when the MPN-SAF-TSS decreased by ≥50% compared to baseline for the first time.

    Time frame: Up to 60 weeks

  8. Progression-free survival (PFS)

    The time interval from the first dose to the date of the occurrence of any of the following events, whichever occurs first:(1) Spleen volume increased by ≥25% compared with the screening period ; (2) Death caused by any cause.

    Time frame: Up to 120 weeks

  9. Leukemia free survival (LFS)

    The time interval from the date of the first dose to the date of any of the following events, whichever occurs first: (1) the date of the first bone marrow smear showing the original cell ≥20% ;(2) The first peripheral blood smear showed that the original cells ≥ 20% and the absolute value of the original cells ≥1×10\^9/L and lasted for at least 2 weeks; (3) Death caused by any reason.

    Time frame: Up to 120 weeks

  10. Overall Survival (OS)

    The time from the first time the subject received treatment to death due to any cause

    Time frame: Up to 120 weeks

  11. Incidence of adverse events (AEs)

    Incidence rate of all adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)

    Time frame: Baseline up to 120 weeks

  12. Severity of adverse events (AEs)

    Severity of all adverse medical events that occur after the subject receives the investigational drug, evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)

    Time frame: Baseline up to 120 weeks

07

Study locations

5 sites
  • The Second People's Hospital of Hefei
    Hefei, Anhui 230012, China
  • Hennan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • Xijing Hospital of the Fourth Military Medical University
    Xi'an, Shaanxi 710032, China
  • People's Hospital of Tianjin
    Tianjin, Tianjin Municipality 300122, China
  • The First Affiliated Hospital Zhejiang University School Of Medicine
    Hangzhou, Zhejiang 310003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Dec 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 7, 2024
StartActual
May 13, 2024
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06245941
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
May 13, 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Jan 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bcl-2 Inhibitor TQB3909

Start the discussion